A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

@article{Stennicke2013ANB,
  title={A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.},
  author={Henning R. Stennicke and Marianne Kjalke and Ditte Maria Karpf and Kristoffer W. Balling and Peter B. Johansen and Torben Elm and Kristine \Ovlisen and Flemming V. Moeller and H Lindgreen Holmberg and Charlotte Nini Gudme and Egon Persson and Ida Hilden and Hermann Pelzer and Henrik Rahbek-Nielsen and Christina Jespersgaard and Are Bogsnes and Anette Amstrup Pedersen and Anne Krogh Kristensen and Bernd Peschke and Wendy Kappers and F Rode and Lars Thim and Mikael Tranholm and Mirella Ezban and Eva H. N. Olsen and S\oren Erik Bj\orn},
  journal={Blood},
  year={2013},
  volume={121 11},
  pages={2108-16}
}
Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a longer half-life was developed without changing the protein structure. FVIII-polyethylene glycol (PEG) conjugates were prepared using an enzymatic process coupling PEG (ranging from 10 to 80 kDa) selectively to a unique O-linked glycan in the FVIII B-domain. Binding to von Willebrand factor (VWF) was maintained for all… CONTINUE READING